| A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia (NCT04980885) | Akeso | 2021-08-13 |
| CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease (NCT04526288) | Fred Hutchinson Cancer Center | 2021-08-09 |
| Application of Nanopore Sequencing in Newly Diagnosed Acute Myeloid Leukemia Patients With Bloodstream Infection (NCT05016752) | The First Affiliated Hospital of Soochow University | 2021-08-05 |
| Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia (NCT04789408) | Kite, A Gilead Company | 2021-07-19 |
| Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML (NCT04887259) | Lava Therapeutics | 2021-07-12 |
| Removing Transfusion Dependence as a Barrier to Hospice Enrollment (NCT05063591) | Adam Olszewski | 2021-07-09 |
| ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (NCT05010122) | M.D. Anderson Cancer Center | 2021-07-08 |
| Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid Leukemia (NCT04964505) | Brian Jonas | 2021-07-02 |
| Clinical Study of DC-AML Cells in the Treatment of Acute Myeloid Leukemia (NCT05000801) | Affiliated Hospital to Academy of Military Medical Sciences | 2021-07-01 |
| Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated (NCT04778397) | Gilead Sciences | 2021-07-01 |
| TAA05 Cell Injection in the Treatment of Recurrent / Refractory Acute Myeloid Leukemia (NCT05017883) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2021-07-01 |
| Donor Immune Cell Therapy for Acute Myeloid Leukemia (NCT05333705) | First Affiliated Hospital Xi'an Jiaotong University | 2021-07-01 |
| Anti-Leukemia Immune Responses After Irradiation of Extramedullary Tumors (NCT05035706) | M.D. Anderson Cancer Center | 2021-06-30 |
| Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study (NCT05972577) | Ohio State University Comprehensive Cancer Center | 2021-06-11 |
| Role of Adrenomedullin in Leukemic Endosteal/Vascular Niches (NCT04460963) | Gruppo Italiano Malattie EMatologiche dell'Adulto | 2021-06-09 |
| Validation Study of a New Cytokine-based Dynamic Stratification Based on FLt3 Ligand Plasma Concentration Kinetic Profile and IL-6 Concentration During Induction of Acute Myeloid Leukemia (NCT04641910) | Nantes University Hospital | 2021-06-08 |
| Outcome of Patients With CBF and/or NPM1-mutated AML in First Molecular Relapse. (NCT04931992) | University Hospital, Angers | 2021-06-01 |
| Study of Chidamide Combined With Cladribine in Refractory/Relapsed Acute Myeloid Leukemia (NCT05330364) | Ge Zheng | 2021-06-01 |
| Humanized CD7 CAR T-cell Therapy for r/r CD7+ Acute Leukemia (NCT04762485) | The First Affiliated Hospital of Soochow University | 2021-06-01 |
| A Study of BGB-11417 in Participants With Myeloid Malignancies (NCT04771130) | BeOne Medicines | 2021-05-24 |
| Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (NCT04774393) | M.D. Anderson Cancer Center | 2021-05-24 |
| Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML (NCT04842604) | Pfizer | 2021-05-17 |
| The Registry of Oncology Outcomes Associated With Testing and Treatment (NCT04028479) | Taproot Health | 2021-05-05 |
| A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05) (NCT04755244) | ALX Oncology Inc. | 2021-05-05 |
| Relatlimab With Nivolumab and 5-Azacytidine for the Treatment of AML (NCT04913922) | Ludwig-Maximilians - University of Munich | 2021-05-05 |
| Study of Periodontitis and Blood Stream Infection in AML Patients Receiving Chemotherapy (NCT04858594) | Masonic Cancer Center, University of Minnesota | 2021-05-04 |
| BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS (NCT04827719) | Groupe Francophone des Myelodysplasies | 2021-05-01 |
| PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AML (NCT04722952) | The First Affiliated Hospital of Soochow University | 2021-05-01 |
| Dociparstat in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia (NCT04571645) | Jazz Pharmaceuticals | 2021-04-30 |
| Minimal Residual Disease Evaluation on Cryopreserved Ovarian Fragments in Younger Patients Treated for Acute Myeloid Leukemia (NCT04679285) | University Hospital, Lille | 2021-04-26 |
| Immune Profile of Acute Myeloid Leukemia Patients Receiving Azacitidine Plus Venetoclax Induction Chemotherapy (NCT06279572) | Mayo Clinic | 2021-04-22 |
| A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML (NCT04730258) | Treadwell Therapeutics, Inc | 2021-04-16 |
| Phase I/II Study of Enhanced CD33 CAR T Cells in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (NCT04835519) | Beijing Boren Hospital | 2021-04-08 |
| A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia (NCT04896112) | Lynk Pharmaceuticals Co., Ltd | 2021-04-08 |
| Gemtuzumab Ozogamicin in Induction and Glasdegib in Postremission Therapy in Patients With AML (Acute Myeloid Leukemia) (NCT04093505) | University Hospital Heidelberg | 2021-04-01 |
| TL-895 and KRT-232 Study in Acute Myeloid Leukemia (NCT04669067) | Telios Pharma, Inc. | 2021-03-31 |
| A Telehealth Advance Care Planning Intervention for Older Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome (NCT04745676) | University of Rochester | 2021-03-25 |
| Phase I/II Trial of S65487 Plus Azacitidine in Acute Myeloid Leukemia (NCT04742101) | Institut de Recherches Internationales Servier | 2021-03-10 |
| Efficacy and Safety of Cladribine in Combination With CAG in Newly Diagnosed Unfit Patients With AML (NCT04254640) | Sun Yat-sen University | 2021-03-01 |
| Prognostic Value of CD318 in AML at Assiut University Hospital. (NCT04708444) | Shimaa Arafa Ibrahim | 2021-03-01 |
| Venetoclax+HMA+Aclarubicin Versus Venetoclax+HMA in Treatment-Naive Elderly Patients With AML (NCT05264883) | The First Affiliated Hospital with Nanjing Medical University | 2021-03-01 |
| Application of Health Education Path of Traditional Chinese Medicine Nursin (NCT05563207) | Shijiazhuang Pingan Hospital | 2021-03-01 |
| Prospective and Retrospective Observational Evaluation of Real World Outcome of Unfit AML Patients Treated With the Combination Venetoclax Plus Hypomethylating Agents, Under the Italian Law No.648/96 (NCT04589728) | Gruppo Italiano Malattie EMatologiche dell'Adulto | 2021-02-23 |
| Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia (NCT04746235) | M.D. Anderson Cancer Center | 2021-02-22 |
| Methods of T Cell Depletion Trial (MoTD) (NCT04888741) | University of Birmingham | 2021-02-22 |
| Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT (NCT04629430) | University of Virginia | 2021-02-19 |
| BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia (NCT04214249) | National Cancer Institute (NCI) | 2021-02-17 |
| Tagraxofusp in Patients With CD123+ or With BPDCN-IPh-like Acute Myeloid Leukemia (NCT04342962) | Gruppo Italiano Malattie EMatologiche dell'Adulto | 2021-02-16 |
| BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia (NCT04284787) | National Cancer Institute (NCI) | 2021-02-16 |
| Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML) (NCT04657081) | Taiho Oncology, Inc. | 2021-02-09 |
| Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2 (NCT04229979) | Sellas Life Sciences Group | 2021-02-08 |
| Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia (NCT04190550) | National Cancer Institute (NCI) | 2021-02-04 |
| Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies (NCT04195633) | Fred Hutchinson Cancer Center | 2021-01-25 |
| Infusion of Alloreactive nk Cells for Mrd-positive Aml Patients (NCT06885476) | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 2021-01-22 |
| NKG2D CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Myeloid Leukemia (NCT04658004) | Zhejiang University | 2021-01-15 |
| Phase I Clinical Trial of RC1012 Injection in Patients With r/r AML (NCT05471323) | Guangdong Ruishun Biotech Co., Ltd | 2021-01-14 |
| Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (NCT04659616) | OHSU Knight Cancer Institute | 2021-01-14 |
| NTX-301 in MDS/AML (NCT04167917) | University of Alabama at Birmingham | 2021-01-06 |
| Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005) (NCT04095858) | Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2021-01-05 |
| A Post-treatment Program to Identify and Manage Complications Related to Oncology or Hematology Treatments in Cancer Survivors. (NCT04671693) | Centre Leon Berard | 2020-12-24 |
| A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms (NCT04637009) | Astex Pharmaceuticals, Inc. | 2020-12-21 |
| Observational Study for the Evaluation of Incidence of Familial AML/MDSs in Patients With Myeloid Neoplasms (NCT04460950) | Gruppo Italiano Malattie EMatologiche dell'Adulto | 2020-12-16 |
| A Trial to Evaluate the Safety and Efficacy of oNKord® in Subjects With Acute Myeloid Leukemia (NCT04632316) | Glycostem Therapeutics BV | 2020-12-08 |
| A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS (NCT04358393) | Ascentage Pharma Group Inc. | 2020-12-04 |
| Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia (NCT04512105) | University of California, Irvine | 2020-12-02 |
| National Longitudinal Cohort of Hematological Diseases (NCT04645199) | Institute of Hematology & Blood Diseases Hospital, China | 2020-12-01 |
| Study of Anti-CD33/CLL1 CAR-NK in Acute Myeloid Leukemia (NCT05215015) | Wuxi People's Hospital | 2020-11-30 |
| A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) (NCT04609826) | Janssen Research & Development, LLC | 2020-11-26 |
| Cardiovascular Reserve Evaluation in Survivors of Transplant, CREST Study (NCT04537871) | City of Hope Medical Center | 2020-11-18 |
| IL3 CAR-T Cell Therapy for Patients With CD123 Positive Relapsed and/or Refractory Acute Myeloid Leukemia (NCT04599543) | Zhejiang University | 2020-11-15 |
| National Cancer Institute "Cancer Moonshot Biobank" (NCT04314401) | National Cancer Institute (NCI) | 2020-11-11 |
| Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers (NCT04092179) | University Health Network, Toronto | 2020-11-05 |
| TP-0903 for the Treatment of FLT3 Mutated Acute Myeloid Leukemia (NCT04518345) | Uma Borate | 2020-11-05 |
| A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420. (NCT04580121) | Hoffmann-La Roche | 2020-11-04 |
| Chemotherapy-related Cognitive Impairment and Acute Leukemia (NCT04644419) | UNC Lineberger Comprehensive Cancer Center | 2020-11-03 |
| Study to Evaluate the Safety and Tolerability of EP0042 (NCT04581512) | Ellipses Pharma | 2020-11-02 |
| Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients (NCT06379360) | The First Affiliated Hospital of Soochow University | 2020-11-01 |
| FT538 in Subjects With Advanced Hematologic Malignancies (NCT04614636) | Fate Therapeutics | 2020-10-17 |
| Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant (NCT04511130) | Marker Therapeutics, Inc. | 2020-10-14 |
| Phase 1 First in Human Study of ZN-d5 as a Single Agent (NCT04500587) | K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. | 2020-10-13 |
| A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS (NCT04477291) | Aptose Biosciences Inc. | 2020-10-06 |
| Immunophenotyping and Xist Gene in AML (NCT04288739) | Assiut University | 2020-10-02 |
| Extramedullary Acute Myeloid Leukemia (eAML): Retrospective Single Center Cohort Study, Clinicopathological, Molecular Analysis and Survival Outcomes (NCT05057299) | King Hussein Cancer Center | 2020-10-01 |
| NK Cell Infusion for Patients With Acute Myeloid Leukemia (NCT04221971) | Peking University People's Hospital | 2020-10-01 |
| 2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/II (NCT03941769) | M.D. Anderson Cancer Center | 2020-09-29 |
| A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies (NCT04543305) | Prelude Therapeutics | 2020-09-28 |
| Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in Treatment of Patients With Acute Myeloid Leukemia (NCT04485052) | Innovent Biologics (Suzhou) Co. Ltd. | 2020-09-25 |
| Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML (NCT04168502) | Gruppo Italiano Malattie EMatologiche dell'Adulto | 2020-09-24 |
| SARS-CoV-2 Donor-Recipient Immunity Transfer (NCT04666025) | City of Hope Medical Center | 2020-09-23 |
| Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers (NCT04553692) | IGM Biosciences, Inc. | 2020-09-23 |
| A Study of XY0206 Tablets in Patients With Relapsed / Refractory Acute Myeloid Leukemia (NCT04471064) | Shijiazhuang Yiling Pharmaceutical Co. Ltd | 2020-09-15 |
| RN-Led Palliative and Supportive Care Intervention (NCT04570709) | UNC Lineberger Comprehensive Cancer Center | 2020-09-14 |
| Early Prophylactic Donor Lymphocyte Infusion After Allo-HSCT for Patients With AML (NCT03597321) | Institut Paoli-Calmettes | 2020-09-07 |
| Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC) (NCT04385290) | Technische Universität Dresden | 2020-09-04 |
| Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients (NCT04920500) | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | 2020-09-04 |
| Could Ki-67 be Used as a Diagnostic or Prognostic Marker in Hemato-oncological Diagnostics? (NCT04517175) | Maastricht University | 2020-09-01 |
| A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy (NCT04150029) | Novartis Pharmaceuticals | 2020-09-01 |
| Haplo Peripheral Blood Sct In GVHD Prevention (NCT04473911) | Zachariah Michael DeFilipp | 2020-08-14 |
| A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies (NCT04227847) | Seagen, a wholly owned subsidiary of Pfizer | 2020-08-07 |
| Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation (NCT03953898) | National Cancer Institute (NCI) | 2020-08-04 |